Research status of suterizumab in the treatment of neuromyelitis optica spectrum disorders
10.13699/j.cnki.1001-6821.2024.22.026
- VernacularTitle:萨特利珠单抗在视神经脊髓炎谱系疾病治疗中的研究现状
- Author:
Yun-fei BAI
1
;
Zi-yi GAO
;
Yue-hong YUE
;
Xiang-jian XIAO
Author Information
1. 华北理工大学研究生院,河北唐山 063000
- Publication Type:Journal Article
- Keywords:
suterizumab;
neuromyelitis optica spectrum disorders;
interleukin-6 receptor inhibitors;
effectiveness;
security
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(22):3348-3352
- CountryChina
- Language:Chinese
-
Abstract:
Neuromyelitis optica spectrum disorders(NMOSD)is a recurrent disease with significant neurological deficits,which can seriously affect the quality of life of patients.In recent years,the interleukin-6 receptor suppressor suterizumab has shown outstanding performance in the treatment of NMOSD,which can effectively reduce the recurrence rate and have fewer adverse drug reactions.This article reviews the mechanism,efficacy and adverse drug reactions of suterizumab in the treatment of NMOSD.
